Sou FM, Chen CH, Huang PY, Tsai MC, Yen YH, Lu SN, Hung CH, Kuo YH*. Strategies of hepatitis C virus elimination for people who inject drugs receiving opioid agonist therapy in the era of direct-acting antivirals. Adv Dig Med. 2024 Dec;11:189–195.
Hsiao YW, Sou FM, Wang JH, Chen YH, Tsai MC, Hu TH, Hung CH, Chen CH, Kuo YH*. Well-controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib. Kaohsiung J Med Sci. 2023 Dec;39(12):1233-1242. (SCI)
Kuo YH, Huang TH, Yen YH, Lu SN, Wang JH, Hung CH, Chen CH, Tsai MC, Kee KM*. Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation. Cancers. 2023 Jun 12;15(12):3156. (SCI)
Kuo YH, Huang TH, Wang JH, Chen YY, Tsai MC, Chen YH, Lu SN, Hu TH, Chen CH, Hung CH*. Well-Controlled Viremia Predicts the Outcome of Hepatocellular Carcinoma in Chronic Viral Hepatitis Patients Treated with Sorafenib. Cancers (Basel). 2022 Aug 17;14(16):3971. (SCI)
Chen HY, Kee KM, Lu SN, Wang JH, Chen CH, Hung CH, Yen YH, Kuo YH*. Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization. J Formos Med Assoc. 2022 Apr;121(4):778-786. (SCI)
Kuo YH, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, Wang JH*. Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus. Kaohsiung J Med Sci. 2022 Mar;38(3):268-276. (SCI)
Kuo YH, Lu SN, Chen YY, Kee KM, Yen YH, Hung CH, Hu TH, Chen CH, Wang JH*. Real world Lenvatinib versus Sorafenib in patients with advanced hepatocellular carcinoma: A Propensity Score Matching analysis. Front Oncol. 2021 Oct 25;11:737767. (SCI)
Lee YC, Wang JH, Chen CH, Hung CH, Lo KC, Yen YH, Kee KM, Hu TH, Lu SN*, Kuo YH*. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study. Kaohsiung J Med Sci. 2021 Oct;37(10):894-902. (SCI)
Kuo YH, Yen YH, Chen YY, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, Wang JH*. Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. Front Oncol. 2021 May 31;11:683341. (SCI)
Kuo YH , Wang JH, Hung CH, Lu SN, Hu TH*,Chen CH*.Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. Hepatol Int. 2021 Apr;15(2):301-309. (SCI)
Kuo YH, Wang JH, Chang KC, Hung CH, Lu SN, Hu TH, Yen YH, Kee KM, Chen CH*. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment. Invest New Drugs. 2020 Feb;38(1):202-210. (SCI)
Kuo YH, Kee KM, Hsu NT, Wang JH, Hsiao CC, Chen Y, Lu SN*. Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening. PLoS One. 2019 Oct 22;14(10):e0222196. (SCI)
Kuo YH, Lu SN*. Letter: the association between chronic viral hepatitis and metabolic syndrome - Authors' reply. Aliment Pharmacol Ther. 2019 Jan;49(2):233-234. (SCI)
Kuo YH, Lu SN*. Editorial: hepatitis B, fatty liver and metabolic syndrome-Interaction or co-existence? Authors' reply. Aliment Pharmacol Ther. 2018 Nov;48(10):1162-1163. (SCI)
Kuo YH, Kee KM, Wang JH, Hsu NT, Hsiao CC, Chen Y, Lu SN*. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. Aliment Pharmacol Ther. 2018 Nov;48(9):993-1002. (SCI)
Kuo YH, Wu IP, Wang JH, Hung CH, Rau KM, Chen CH, Kee KM, Hu TH, Lu SN*. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Invest New Drugs. 2018 Apr;36(2):307-314. (SCI)
Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, Hu TH, Lu SN* . Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol. 2017 Dec;32(12):1975-1981. (SCI)
Kuo YH, Tsai MC, Kee KM, Chang KC, Wang JH, Lin CY, Lin SC, Lu SN*. Associated Factors for Metabolic Syndrome in the Older Adults with Chronic Virus Hepatitis in the Community. PLoS One. 2016 May 13;11(5):e0155544. (SCI)
Kuo YH, Lu SN*. Role of serum quantitative hepatitis B surface antigen (HBsAg) in HBsAg carriers in a follow-up community study. Kaohsiung J Med Sci. 2015 July; 31(7):386-387. (SCI) (letter)
Kuo YH, Chen PF, Wang JH, Chang KC, Kee KM, Tsai MC, Lin CY, Lin SC, Tsai LS, Chen SC, Lu SN*. Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care. PLoS One. 2015 May 13;10(5):e0126031. (SCI)
Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Lu SN*. Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: A follow-up study of an elderly cohort. Kaohsiung J Med Sci. 2015 Feb; 31(2): 102–107. (SCI)
Kuo YH, Chung KC, Hung CH, Lu SN, Wang JH*. The impact of general anesthesia on radiofrequency ablation of hepatocellular carcinoma. The Kaohsiung Journal of Medical Sciences. 2014 Nov; 30(11): 559-565.
Kuo YH, Lu SN, Chen CH, Chang KC, Hung CH, Tai WC, Tsai MC, Tseng PL, Hu TH, Wang JH*. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS One. 2014 Mar 28;9(3):e93160.
Wang JH*#, Kuo YH#, Wang CC, Chen CL, Cheng YF, Hsu HC, Lu SN. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. Dig Liver Dis. 2013 Jun;45(6):510-515. (SCI) (#: co-first author)
Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Chen CH, Lu SN*. Is hepatitis C virus core antigen an adequate marker for community screening? J Clin Microbiol. 2012 Jun;50(6):1989-93. (SCI)
Kuo YH, Chuang TW, Hung CH*, Chen CH, Wang JH, Hu TH, Lu SN, Lee CM. Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy. J Formos Med Assoc. 2011 Jun;110(6):363-71. (SCI)
Kuo YH, Lu SN, Hung CH, Kee KM, Chen CH, Hu TH, Lee CM, Changchien CS, Wang JH*. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis. Hepatol Int. 2010 Oct 8;4(4):700-6. (SCI)
Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH, Lee CM, Wang JH*. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010 Mar;46(4):744-51. (SCI)
Kuo YH, Chen CH, Wang JH, Hung CH, Tseng PL, Lu SN, Changchien CS, Lee CM*. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol. 2010;45(1):75-81. (SCI)
Kuo YH, Kuo CM, Chou YP, Chuah SK, Chiu YC, Wu KL*, Rayner CK, Eng HL. Gastric ulcer infected with candida: risk factors and endoscopic appearance. Taiwan J Gastroenterol 2009, 26(4):285-90.
Kuo YH, Wang JH, Lu SN, Hung CH*, Wei YC, Hu TH, Chen CH, Yen YH, Lee CM, Eng HL. Natural course of hepatic focal nodular hyperplasia: a long-term follow-up study with sonography. J Clin Ultrasound. 2009 Mar-Apr;37(3):132-7. (SCI)
Kuo YH, Wang JH*, Hu TH, Lee CM. Primary Hepatocellular Carcinoma in Ectopic Liver and Later Metastasis to Mother Liver: A Case Report and Review of the Literature. J Intern Med Taiwan 2008, 19(1):422-7.
